Arecor Therapeutics PLC (AREC) Price & Analysis

Compare

3 Followers

AREC Stock Chart & Stats

Day’s Range― - ―

52-Week Range35.40p - 115.10p

Previous CloseN/A

Volume5.49K

Average Volume (3M)20.53K

Market Cap

£17.93M

Enterprise Value63.77M

Total Cash (Recent Filing)£3.26M

Total Debt (Recent Filing)£232.00K

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Sep 18, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding37,756,600

10 Day Avg. Volume34,177

30 Day Avg. Volume20,528

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)15.89

Price to Sales (P/S)0.00

P/FCF Ratio-25.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£45.00

Price Target Upside-5.26% Downside

Rating ConsensusHold

Number of Analyst Covering1

Arecor Therapeutics PLC News

PremiumCompany Announcements

Arecor Therapeutics Grants New Share Options to Drive Growth

1M ago

PremiumCompany Announcements

Arecor Therapeutics Passes All AGM Resolutions, Strengthening Governance

1M ago

PremiumCompany Announcements

Arecor Therapeutics Announces Board Change with Dr. Alan Smith’s Retirement

1M ago

PremiumCompany Announcements

Arecor Executives Show Confidence with Share Purchases

2M ago

PremiumCompany Announcements

Arecor Partners with Skye Bioscience to Enhance Obesity Treatment

2M ago

PremiumCompany Announcements

Arecor Chair Increases Stake with Share Purchase

2M ago

PremiumCompany Announcements

Arecor Therapeutics Releases 2024 Annual Report and Announces AGM

2M ago

PremiumCompany Announcements

Arecor Therapeutics to Present Annual Results on Investor Platform

3M ago

See All GB:AREC News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

5.27% Insiders

―

Mutual Funds

― Other Institutional Investors

94.73% Public Companies and

Individual Investors

Detailed Ownership Overview >

AREC FAQ

What was Arecor Therapeutics PLC’s price range in the past 12 months?

Arecor Therapeutics PLC lowest share price was 35.40p and its highest was 115.10p in the past 12 months.

What is Arecor Therapeutics PLC’s market cap?

Arecor Therapeutics PLC’s market cap is £17.93M.

When is Arecor Therapeutics PLC’s upcoming earnings report date?

Arecor Therapeutics PLC’s upcoming earnings report date is Sep 18, 2025 which is in 69 days.

How were Arecor Therapeutics PLC’s earnings last quarter?

Arecor Therapeutics PLC released its earnings results on Apr 22, 2025. The company reported -0.155p earnings per share for the quarter, missing the consensus estimate of N/A by -0.155p.

Is Arecor Therapeutics PLC overvalued?

According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arecor Therapeutics PLC pay dividends?

Arecor Therapeutics PLC does not currently pay dividends.

What is Arecor Therapeutics PLC’s EPS estimate?

Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arecor Therapeutics PLC have?

Arecor Therapeutics PLC has 37,756,600 shares outstanding.

What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?

Arecor Therapeutics PLC reported an EPS of -0.155p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Arecor Therapeutics PLC?

Currently, no hedge funds are holding shares in GB:AREC

Company Description

Arecor Therapeutics PLC

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

AREC Stock 12 Month Forecast

Average Price Target

45.00p

▼(-5.26%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"37":"37p","58":"58p","79":"79p","100":"100p","121":"121p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">45.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">45.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">45.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[37,58,79,100,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.5,43.61538461538461,43.73076923076923,43.84615384615385,43.96153846153846,44.07692307692308,44.19230769230769,44.30769230769231,44.42307692307692,44.53846153846154,44.65384615384615,44.76923076923077,44.88461538461539,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.5,43.61538461538461,43.73076923076923,43.84615384615385,43.96153846153846,44.07692307692308,44.19230769230769,44.30769230769231,44.42307692307692,44.53846153846154,44.65384615384615,44.76923076923077,44.88461538461539,{"y":45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.5,43.61538461538461,43.73076923076923,43.84615384615385,43.96153846153846,44.07692307692308,44.19230769230769,44.30769230769231,44.42307692307692,44.53846153846154,44.65384615384615,44.76923076923077,44.88461538461539,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":120,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":92.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":82.5,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":75,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.5,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":73.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.5,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":50,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":42.5,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":38,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":38,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.5,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >